Search Tufts Medicine

Displaying 181 - 187 of 187
clinical trial
...

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: immediate daratumumab + VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated wi
clinical trial
...

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Articles
June 9, 2020
In response to the COVID-19 pandemic, routine in-person healthcare visits have been temporarily put on hold in efforts to conserve personal protective equipment and to maintain social distancing. As the Centers for Medicare & Medicaid Services eased restrictions on telehealth, virtual doctor visits have become the temporary norm.
page
...
Our principal investigators and trainees have received a number of honors and awards for their leadership and accomplishments in research that advances the understanding of preterm birth and its complications, maternal obesity and fetal and neonatal genomic medicine. We are grateful for the recognition from our peers and the honors bestowed on us by international and national associations and institutions for our contributions.
Publications + Awards
department
The Division of Geographic Medicine + Infectious Diseases is an international center of excellence in infectious disease, inpatient and outpatient treatment, research, and infectious disease fellowship training.